Vivoo has raised $21.0M in total across 3 funding rounds.
Vivoo's investors include Draper Associates, Visionaire Ventures, Herty Tammo, Jaan Tallinn.
Vivoo is a San Francisco-based wellness-tech company founded in 2017 that develops at-home urine testing strips analyzed via a mobile app, providing real-time insights on nine health parameters including hydration, vitamin C, magnesium, calcium, sodium, oxidative stress, pH, ketones, and protein levels.[1][2][5] It serves health-conscious individuals seeking proactive wellness management, solving the problem of inaccessible, personalized health data by delivering AI-powered nutritional recommendations, meal planning via its virtual assistant Welly, wearable integrations, and custom supplements—all backed by partnerships with doctors, dietitians, and nutritionists.[1][2][3][5] With over $19M in funding from investors like Draper Associates, Techstars, and 500 Startups, and around 60 employees, Vivoo generates revenue through test kit sales and app subscriptions, emphasizing sustainability and inclusivity.[1][2][4]
Vivoo emerged from a vision to revolutionize at-home health monitoring, starting in a modest lab with cutting-edge image processing technology for urine test analysis.[3] Co-founders Miray Tayfun (CEO), along with CFO and COO (names not specified in sources), drove the idea amid a healthcare landscape lacking accessible, personalized testing, launching in 2017 as the first wellness app tying urine tests to nutrition/lifestyle advice.[1][3][6] Early traction included Techstars backing and a $6M Series A led by Tim Draper in 2021, building on pre-seed from 500 Startups, with total funding reaching $19M+ and expansion to personalized supplements and a library of 300+ wellness articles.[2][4]
Vivoo rides the explosive growth of direct-to-consumer (DTC) wellness tech and personalized health monitoring, fueled by post-pandemic demand for at-home solutions amid rising chronic wellness issues like dehydration and nutrient deficiencies.[2][5][6] Timing aligns with AI advancements in image analysis and wearables boom, enabling seamless data integration that traditional healthcare can't match in speed or affordability.[1][3] Market forces like consumer empowerment trends and sustainability mandates favor Vivoo, as it democratizes lab-grade insights (previously clinic-bound) and influences the ecosystem by setting standards for AI-driven, expert-validated DTC testing—potentially expanding to more biomarkers and global partnerships.[3][5]
Vivoo is poised to scale as a leader in accessible wellness tech, with next steps likely including broader biomarker tests, deeper AI personalization, and international expansion beyond USA/Canada.[1][5] Trends like AI health coaching, wearable interoperability, and preventive wellness will propel growth, evolving its influence from niche testing to a full-stack platform shaping how consumers own their body data daily—echoing its founding mission to make health monitoring effortless and integral to life.[2][3]
Vivoo has raised $21.0M across 3 funding rounds. Most recently, it raised $13.0M Series B in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $13.0M Series B | Draper Associates, Visionaire Ventures, Herty Tammo, Jaan Tallinn | |
| Jun 1, 2021 | $6.0M Series A | Draper Associates, Visionaire Ventures, Herty Tammo, Jaan Tallinn | |
| Jan 1, 2020 | $2.0M Seed | Draper Associates, Visionaire Ventures, Herty Tammo, Jaan Tallinn |
